John M. Hampton

John M. Hampton

Auto-generated profile, based on publicly available information

John M. Hampton

Carbone Cancer Center, Madison, WI

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2021 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
NRNicolien van Ravesteyn
Nicolien van Ravesteyn
CSClyde Schechter Schechter
Clyde Schechter Schechter
JHJohn M Hampton
John M Hampton
OAOguzhan Alagoz
Oguzhan Alagoz
JBJeroen J van Den Broek
Jeroen J van Den Broek
TNthe Breast Cancer Surveillance Consortium and the Cancer Intervention and Surveillance Modeling Network
the Breast Cancer Surveillance Consortium and the Cancer Intervention and Surveillance Modeling Network
Background: A paucity of research addresses breast cancer screening strategies for women at lower-than-average breast cancer risk. The aim of this study was to examine screening harms and benefits among women aged 50-74 years at lower-than-average breast cancer risk by breast density. Methods: Three well-established, validated Cancer Intervention and Surveillance Network models were used to estimate the lifetime benefits and harms of different screening scenarios, varying by screening interval (biennial, triennial). Breast cancer deaths averted, life-years and quality-adjusted life-years gained, false-positives, benign biopsies, and overdiagnosis were assessed by relative risk (RR) level (0.6, 0.7, 0.85, 1 [average risk]) and breast density category, for US women born in 1970. Results: Screening benefits decreased proportionally with decreasing risk and with lower breast density. False-positives, unnecessary biopsies, and the percentage overdiagnosis also varied substantially by breast density category; false-positives and unnecessary biopsies were highest in the heterogeneously dense category. For women with fatty or scattered fibroglandular breast density and a relative risk of no more than 0.85, the additional deaths averted and life-years gained were small with biennial vs triennial screening. For these groups, undergoing 4 additional screens (screening biennially [13 screens] vs triennially [9 screens]) averted no more than 1 additional breast cancer death and gained no more than 16 life-years and no more than 10 quality-adjusted life-years per 1000 women but resulted in up to 232 more false-positives per 1000 women. Conclusion: Triennial screening from age 50 to 74 years may be a reasonable screening strategy for women with lower-than-average breast cancer risk and fatty or scattered fibroglandular breast density.

1 August 2019 in Radiology
Verified
Journal Article
Closed access
EBElizabeth S. Burnside
Elizabeth S. Burnside
ATAmy Trentham-Dietz
Amy Trentham-Dietz
CSChristina M. Shafer
Christina M. Shafer
JHJohn M. Hampton
John M. Hampton
OAOguz Alagoz
Oguz Alagoz
LWLee G. Wilke
Lee G. Wilke
Hypothetical screening scenarios show that for women 40–49 years old, initiating age-based mammography screening starting at age 45 reveals more cancers and results in more false-positive mammogram... BackgroundRisk-based screening in women 40–49 years old has not been evaluated in routine screening mammography practice.PurposeTo use a cross-sectional study design to compare the trade-offs of ri...

1 October 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MWMargaret Walker
Margaret Walker
NLNoelle K. LoConte
Noelle K. LoConte
KLKajua B. Lor
Kajua B. Lor
JHJohn M. Hampton
John M. Hampton
ASAndrea M Schiefelbein
Andrea M Schiefelbein
RVRoberto J. Vidri
Roberto J. Vidri
152 Background: The Hmong people constitute an Asian-American subgroup, accounting for 0.1% of the United States (US) population. Originating from Laos and Vietnam, Hmong individuals fought as secret soldiers for the US during the Vietnam War and later immigrated to the US, with the largest settlements in Minnesota, Wisconsin, and California. The Hmong population has faced various health disparities in the domains of mental health, chronic disease, and cancer. This study seeks to investigate trends in colorectal cancer (CRC) survival in the US Hmong population. Methods: Cases of colon and rectal adenocarcinoma diagnosed between 2004-2017 were identified within the National Cancer Database. Summary statistics of demographic, clinical, socioeconomic, and treatment variables were calculated. Multiple Cox proportional hazard models were constructed using sets of demographic, clinical, socioeconomic, and treatment variables to identify factors associated with overall survival (OS) within the Hmong population diagnosed with CRC. Results: One hundred and twenty (0.01%) Hmong individuals were identified within a total of 881,243 CRC cases. Their average age at diagnosis was 58.9 years, compared 68.7 years for Non-Hispanic White (NHW) individuals (p < 0.01). Over half of Hmong individuals (52.5%) were diagnosed with Stage III or VI disease (NHW, 42.5%, p < 0.03), and they more frequently resided in the lowest median income quartile (p < 0.01), the lowest high school degree achievement quartile (p < 0.01), and had higher rates of Medicaid coverage (p < 0.01) compared to NHWs. When adjusting only for age, sex, stage, and Charlson-Deyo comorbidity score, Hmong individuals had a greater hazard of death compared to their NHW counterparts (HR 1.43, p < 0.01). However, in a multivariable model accounting for all variables suspected to be associated with CRC outcomes, OS was similar between these groups (HR 1.01, p < 0.93). Conclusions: Hmong individuals diagnosed with CRC appear to have similar overall survival to Non-Hispanic Whites despite belonging to lower socioeconomic groups, being diagnosed at a younger age and with a higher proportion of Stage III/VI disease. This may point to a robust response to treatment and resilience within the Hmong community. Future efforts will focus on disseminating this information and developing community-based approaches for health screening and prevention.